Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab
Authors:
- 1 August 2021
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 80 (2) , 149-159
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Molecular classification of urothelial carcinoma: global mRNA classification versus tumour‐cell phenotype classificationThe Journal of Pathology, 2017
- Clonal evolution of chemotherapy-resistant urothelial carcinomaNature Genetics, 2016
- Molecular Drivers of the Non–T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder CancerCancer Immunology Research, 2016
- Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer—Does pT0 Predict Better Survival than pTa/Tis/T1?Journal of Urology, 2016
- Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder CancerEuropean Urology, 2015
- Tumors: Wounds That Do Not Heal—ReduxCancer Immunology Research, 2015
- Trends in the Use of Perioperative Chemotherapy for Localized and Locally Advanced Muscle-invasive Bladder Cancer: A Sign of Changing TidesEuropean Urology, 2015
- Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline ChemotherapyCancer Cell, 2014
- Inferring tumour purity and stromal and immune cell admixture from expression dataNature Communications, 2013
- A Molecular Taxonomy for Urothelial CarcinomaClinical Cancer Research, 2012